2021-11-12T20:09:49-06:00 2020-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2020-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8670 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2021-11-12 1 JON KOBASHIGAWA MD 999009999 KARA ADAMS P00023315 9497942300 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z X JON KOBASHIGAWA MD 8670 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 2474527 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 5 3 0 0 0 0 1944292 2136097 266304 338430 0 0 0 0 2210596 2474527 0 0 0 0 1599359 1653597 0 0 0 601968 722989 2201327 2376586 9269 97941 79180 198494 234130 255504 -154950 -57010 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 2129994 0 338430 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2020: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* SUCCESS WITH FAILURE: THE ART & SCIENCE OF HEART FAILURE MANAGEMENT (MARINA DEL REY, CA) FEBRUARY 21ST, 2020THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, FEBRUARY 21ST, 2020 AT THE MARRIOTT MARINA DEL REY. THE SYMPOSIUM PROVIDED AN IN-DEPTH REVIEW OF DIAGNOSTICS, THERAPEUTIC OPTIONS AND NOVEL TREATMENTS IN ADVANCED HEART FAILURE, MECHANICAL CIRCULATORY SUPPORT AND TRANSPLANTATION. THE PROGRAM DREW OVER 200 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS FROM ACROSS CALIFORNIA. * "CUTTING EDGE OF TRANSPLANTATION (CEOT)" - MARCH 5TH-7TH, 2020 (PHOENIX AZ)THIS ANNUAL CONFERENCE WAS ORGANIZED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, WITH CONTENT DEVELOPED WITH A THEMATIC FOCUS ON "BALANCING EQUITY AND UTILITY IN THE FACE OF AN ORGAN SHORTAGE." SESSIONS FOCUSED ON HEART AND LUNG TRANSPLANTATION WERE BEING DESIGNED, ORGANIZED AND CHAIRED BY DR. KOBASHIGAWA. THE INTERACTIVE SESSIONS ATTRACTED 100 PARTICIPANTS AND INCLUDED A HIGHLY ACCLAIMED EXPERT FACULTY, A MENTORED CASE STUDY SESSION FOR FELLOWS AND NETWORKING OPPORTUNITIES.* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO 8 STUDENTS FOR THE SUMMER OF 2020 (JULY TO SEPTEMBER). THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED AND ALL ACCEPTED FOR PRESENTATION AT THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:UNIVERSITY OF CALIFORNIA, LOS ANGELESUNIVERSITY OF CALIFORNIA, BERKELEYCREIGHTON MEDICAL SCHOOLUNIVERSITY OF UTAH UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE* "THOMAS D. GORDON VISITING PROFESSOR IN ADVANCED HEART DISEASE" NOVEMBER 3RD, 2020 (CONVERTED TO VIRTUAL)IN ITS FOURTH YEAR, THIS ANNUAL VISITING PROFESSORSHIP HAS CONTINUED TO BE SPONSORED AND ORGANIZED BY DR. KOBASHIGAWA. ARRANGEMENTS ARE BEING MADE FOR A 1-DAY VIRTUAL "VISIT" FOR DR. CLYDE YANCEY FROM NORTHWESTERN UNIVERSITY, FEINBERG SCHOOL OF MEDICINE. THIS VIRTUAL VISIT INCLUDED A GRAND ROUNDS LECTURE AND A FELLOWS' PROFESSIONAL DEVELOPMENT DISCUSSION. DR. YANCY'S LECTURE ON "SYSTEMIC RACISM, HEALTH DISPARITIES AND SOCIAL JUSTICE: LESSONS LEARNED IN 2020" WAS TIMELY, INSIGHTFUL AND THOUGH-PROVOKING AND WAS EXTREMELY WELL RECEIVED.* "U.S. FORUM ON OUTCOME MEASURES IN HEART TRANSPLANTATION" NOVEMBER 12TH-13TH, 2020 (CONVERTED TO VIRTUAL)ENDORSED BY THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE UNITED NETWORK OF ORGAN SHARING AND ORGANIZED AND CHAIRED BY DR. KOBASHIGAWA, THE FORUM ON OUTCOME MEASURES IN HEART TRANSPLANTATION WAS HELD VIRTUALLY ON NOVEMBER 12-13TH, 2020. ATTENDED BY 77 EXPERTS REPRESENTING HEART TRANSPLANT PROGRAMS IN ALL REGIONS OF THE UNITED STATES, THE FORUM ALLOWED FOR A ROBUST DISCUSSION ON CURRENT AND POTENTIAL METRICS UTILIZED TO EVALUATE AND SET STANDARDS FOR THE QUALITY OF CARE PROVIDED BY HEART TRANSPLANT CENTERS IN THE UNITED STATES. RECOMMENDATIONS TO REGULATORS FOR REFINING OUTCOMES METRICS THAT BETTER REFLECT PROGRAM QUALITY, ENCOURAGE INNOVATION AND PROMOTE BEST PRACTICES WERE DEVELOPED, WITH A WHITE PAPER CURRENTLY IN FINAL DEVELOPMENT. * "CURRENT TRENDS IN HEART TRANSPLANTATION: PATIENT EDUCATION SERIES" DECEMBER 7TH, 2020 (CONVERTED TO VIRTUAL)THIS PATIENT EDUCATION LECTURE BY DR. JON KOBASHIGAWA COVERS CURRENT TRENDS IN HEART TRANSPLANTATION AND PROVIDING PATIENTS WITH AN OVERVIEW OF CUTTING-EDGE INNOVATIONS IN THE FIELD OF HEART TRANSPLANTATION. THE FORUM WAS ATTENDED BY POST-TRANSPLANT PATIENTS AS WELL AS PATIENTS ON THE WAITING LIST FOR TRANSPLANTATION. CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY CATEGORY; STUDY NAME; PRINCIPAL INVESTIGATOR (PI). 2129994 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 6 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 5 3 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 15821 VENTURA BLVD STE 520 ENCINO CA 91436 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 3574751 247021 THOMAS D GORDON DIRECTOR 1.00 40.00 X 0 92950 113067 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 MICHELE HAMILTON TREASURER 2.00 0.00 X X 0 0 0 JAIME MORIGUCHI MD DIRECTOR 2.00 0.00 X 0 0 0 CHRISTINE SUMBI SECRETARY 40.00 0.00 X 0 219796 31438 VENISE STRAND PROGRAM MANAGER 40.00 0.00 X 0 115571 47787 IRINA COZIANU RESEARCH OPER. MANAGER 40.00 0.00 X 0 126646 34215 MARIA THOTTAM CLINICAL RESEARCH COORD. II 40.00 0.00 X 0 106916 24184 0 4236630 497712 0 0 1 0 0 2136097 2136097 EDUCATIONAL PROGRAMS 611430 336974 336974 CULTURAL PROGRAMS 611710 1456 1456 338430 2474527 338430 0 0 223470 223470 1098789 1098789 71456 71456 148922 148922 110960 110960 53054 37138 15916 2715 2469 246 529576 529576 123088 116934 6154 MOVING/STORAGE 4552 4552 DUES & SUBSCRIPTIONS 3360 3360 LICENSE & TAXES 2750 2750 BANK CHARGES 2288 2288 1606 800 806 2376586 2129994 246592 0 71669 198098 7511 396 107678 107678 0 0 79180 198494 228630 255504 5500 234130 255504 X -154950 -57010 -154950 -57010 79180 198494 X 97941 -1 X 0 0 0 X 1531356 1466549 1603657 1944292 2136097 8681951 1531356 1466549 1603657 1944292 2136097 8681951 8681951 6 0 0 0 0 6 8681957 1348418 1.00000 0.99990 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 70594 70594 0 37084 37084 0 0 0 1 0 0 0 0 0 0 0 EDUARDO MARBAN MD DIRECTOR 0 2505782 0 426253 0 642716 0 211818 0 35203 0 3821772 0 0 CHRISTINE SUMBI SECRETARY 0 191247 0 21644 0 6905 0 18026 0 13412 0 251234 0 0 THOMAS D GORDON DIRECTOR 0 0 0 0 0 92950 0 113067 0 0 0 206017 0 0 VENISE STRAND PROGRAM MANAGER 0 106435 0 9136 0 0 0 23119 0 24668 0 163358 0 0 IRINA COZIANU RESEARCH OPER. MANAGER 0 121319 0 5327 0 0 0 7448 0 26767 0 160861 0 0 PART I, LINE 3 PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. IN ADDITION, ONE INDIVIDUAL HAD RETENTION INCENTIVES WHICH HAD CLIFF-VESTING DATE IN 2020. THE FOLLOWING DIRECTOR AND OFFICER RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2020: CHRISTINE SUMBI 6,599 EDUARDO MARBAN, MD 519,736 FORM 990, PART III, LINE 4A (CONTINUED) HEART FAILURE; GALACTIC (A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION); CHANG HEART FAILURE; A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (REXLEMESTROCEL-L) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; CHANG HEART FAILURE; CARDIOMEMS HF SYSTEM POST APPROVAL STUDY; CZER HEART FAILURE; BARIATRIC SURGERY AND HEART FAILURE; HAMILTON HEART FAILURE; REDUCING LUNG CONGESTION SYMPTOMS USING THE V-WAVE SHUNT IN HEART FAILURE (RELIEVE HF); HAMILTON HEART FAILURE; RISK FACTORS AND OUTCOMES IN ADVANCED HEART DISEASE; KOBASHIGAWA HEART FAILURE; DCM PRECISION MEDICINE STUDY; KRANSDORF HEART FAILURE; DILATED CARDIOMYOPATHY PRECISION MEDICINE STUDY - CARDIAC MRI SUBSTUDY; KRANSDORF HEART FAILURE; HFN LIFE; KRANSDORF HEART FAILURE; A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 90-DAY SUPERIORITY TRIAL TO EVALUATE THE EFFECT ON CLINICAL BENEFIT, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL EMPAGLIFLOZIN 10 MG COMPARED TO PLACEBO, INITIATED IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE (DE NOVO OR DECOMPENSATED CHRONIC HF) WHO HAVE BEEN STABILIZED (EMPULSE); PATEL HEART TRANSPLANT; CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR RESUSCITATION, PRESERVATION AND ASSESSMENT OF HEARTS FROM DONORS AFTER CIRCULATORY DEATH (DCD HEART TRIAL); ESMAILIAN HEART TRANSPLANT; THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR RESUSCITATION, PRESERVATION AND ASSESSMENT OF HEARTS FROM DONORS AFTER CIRCULATORY DEATH CONTINUED ACCESS PROTOCOL (OCS DCD HEART CAP); ESMAILIAN HEART TRANSPLANT; ORGAN CARE SYSTEM (OCS) HEART SYSTEM: HEART EXPAND CONTINUED ACCESS PROTOCOL (CAP); ESMAILIAN HEART TRANSPLANT; THE FREQUENCY AND SIGNIFICANCE OF BLOOD TYPE A1 DONORS TO NON-A1 SUBGROUP RECIPIENTS IN HEART TRANSPLANTATION; KITTLESON HEART TRANSPLANT; PROSPECTIVE SURVEY STUDY; KOBASHIGAWA HEART TRANSPLANT; ATG (A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED, OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5 MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS); KOBASHIGAWA HEART TRANSPLANT; SHORE (SURVEILLANCE HEARTCARE OUTCOMES REGISTRY); KOBASHIGAWA HEART TRANSPLANT; ASSESSING THE CELLULAR AND HUMORAL RESPONSE TO SARS-COV-2 (COVID-19) VACCINATION IN HEART TRANSPLANT RECIPIENTS; KOBASHIGAWA HEART TRANSPLANT; COMPUTER ASSISTED CARDIAC HISTOLOGIC EVALUATION; KOBASHIGAWA HEART TRANSPLANT; INTERHEART: APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY; KOBASHIGAWA HEART TRANSPLANT; LONG TERM OUTCOME FOLLOW-UP OF THE RAD001 B253 STUDY, EVEROLIMUS FOR THE PREVENTION OF ALLOGRAFT REJECTION AND VASCULOPATHY IN CARDIAC-TRANSPLANT RECIPIENTS; KOBASHIGAWA HEART TRANSPLANT; CELL-FREE DNA AND AMR; KOBASHIGAWA HEART TRANSPLANT; TARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; KOBASHIGAWA AND PATEL HEART TRANSPLANT; INFILTRATING B CELLS IN CARDIAC ALLOGRAFT VASCULOPATHY; KRANSDORF HEART TRANSPLANT; IMMUNOLOGIC RISK STUDY; KRANSDORF HEART TRANSPLANT; TRANSPLANT OF REDEEMED ORGANS BY JUDICIOUS ADMINISTRATION OF NEW DIRECT-ACTING ANTIVIRALS FOR HEPATITIS-C HEART RECIPIENTS (TROJAN-C); KRANSDORF HEART TRANSPLANT; A MULTICENTER, RETROSPECTIVE REGISTRY OF THE TOTAL ARTIFICIAL HEART; MORIGUCHI HEART TRANSPLANT; ECULIZUMAB - THE DUET CARDIAC TRIAL; PATEL PULMONARY HYPERTENSION; INCREASE RIN-PH-201 (A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE); HAGE PULMONARY HYPERTENSION; INCREASE RIN-PH-202 (AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE); HAGE PULMONARY HYPERTENSION; OPUS REGISTRY (US-BASED, OBSERVATIONAL, DRUG REGISTRY OF OPSUMIT (MACITENTAN) NEW USERS IN CLINICAL PRACTICE); HAGE PULMONARY HYPERTENSION; RANGER (AN EXTENDED ACCESS PROGRAM TO ASSESS LONG-TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY HYPERTENSION); HAGE PULMONARY HYPERTENSION; SOUTHPAW TDE-HF-301 (A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)); HAGE PULMONARY HYPERTENSION; SOUTHAPW TDE-HF-302 (AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301); HAGE PULMONARY HYPERTENSION; TDE-PH-311 (AN OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION - A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310); HAGE PULMONARY HYPERTENSION; RIN-PH-304: PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PH-COPD); HAGE PULMONARY HYPERTENSION; AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENT GLOBAL IMPRESSION QUESTIONS FOR ACTIVITY-INDUCED SYMPTOMS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE PULMONARY HYPERTENSION; A PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF MACITENTAN IN PATIENTS WITH PULMONARY HYPERTENSION AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION (SOPRANO); MORIGUCHI AMYLOIDOSIS; PHASE 3 GLOBAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION-682884 IN PATIENTS WITH TRANSTHYRETIN MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM); PATEL AMYLOIDOSIS; ATTR- EXT (A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)); PATEL AMYLOIDOSIS; APOLLO-B: A STUDY TO EVALUATE PATISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY); PATEL AMYLOIDOSIS; EIDOS -AG310-301 (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRIBUTE-CM TRIAL)); PATEL AMYLOIDOSIS; CARDIAC AMYLOIDOSIS REGISTRY STUDY; PATEL AMYLOIDOSIS; AMYLOIDOSIS SURVEY; PATEL FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/20 AND 6/30/21 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/20. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER, AS THE SOLE CORPORATE MEMBER, ELECTS BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX-EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT WITH RESPECT TO SUCH ISSUES. THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT, AND ANY OTHER ADVISORS IT DEEMS NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. FORM 990, PART XI, LINE 9: ROUNDING -1. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 ACUTE-CARE, TEACHING AND RESEARCH HOSPITAL CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 15821 VENTURA BLVD STE 520 ENCINO CA 91436 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE 500 LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTH SERVICES CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 CEDARS-SINAI HEALTH SYSTEM 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 300990905 SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONS CA 501(C)(3) LINE 12C, III-FI N/A 0 TORRANCE HEALTH ASSOCIATION 3330 LOMITA BLVD TORRANCE CA 90505 330073515 HEALTH SERVICES CA 501(C)(3) LINE 12B, II CEDARS-SINAI HEALTH SYSTEM 1 TORRANCE MEMORIAL MEDICAL CENTER HEALTH CARE FOUNDATION 3330 LOMITA BLVD TORRANCE CA 90505 953528452 FUNDRAISING CA 501(C)(3) LINE 7 TORRANCE HEALTH ASSOCIATION 1 TORRANCE MEMORIAL MEDICAL CENTER 3330 LOMITA BLVD TORRANCE CA 90505 951644042 HEALTH SERVICES CA 501(C)(3) LINE 3 TORRANCE HEALTH ASSOCIATION 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD SUITE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A 0 0 ISS ASC HOLDINGS LLC 6500 WILSHIRE BLVD 15TH FLOOR LOS ANGELES CA 90048 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A 0 0 CS-BH ASC HOLDINGS LLC 450 N ROXBURY DR SUITE 602 BEVERLY HILLS CA 90210 812246488 HOLDING COMPANY CA N/A 0 0 INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A 0 0 SANTA MONICA IMAGING GROUP LLC 6500 WILSHIRE BLVD 15TH FLOOR LOS ANGELES CA 90048 820760657 IMAGING CENTER CA N/A 0 0 TORRANCE MEMORIAL SURGICAL CENTER LLC I 23560 CRENSHAW BLVD SUITE 104 TORRANCE CA 90505 465259260 OUTPATIENT SURGICAL SERVICES CA N/A 0 0 3565 DEL AMO ASSOCIATES A CALIFORNIA LIMITED PARTNERSHIP 5017 CARMEN STREET TORRANCE CA 90503 330554737 RENTAL REAL ESTATE CA N/A 0 0 90210 ASC VENTURE LLC 450 N ROXBURY DR SUITE 602 BEVERLY HILLS CA 90210 134341801 AMBULATORY SURGERY CENTER CA N/A 0 0 OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLOOR LOS ANGELES CA 90048 954522779 INACTIVE CA N/A C 1 CENTINELA FREEMAN HOLDINGS INC 6500 WILSHIRE BLVD STE 2250 LOS ANGELES CA 90048 593811890 REAL ESTATE HOLDINGS CA N/A C 1 OTOHARMONICS CORPORATION 811 SW 6TH AVE STE 1000 PORTLAND OR 97204 461119421 INACTIVE DE N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0